Elimusertib - Bayer
Alternative Names: BAY-1895344; BAY-1895344 HClLatest Information Update: 02 Jul 2024
At a glance
- Originator Bayer
- Developer Bayer; National Cancer Institute (USA)
- Class Antineoplastics; Morpholines; Naphthyridines; Pyrazoles; Small molecules
- Mechanism of Action ATR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- No development reported Head and neck cancer; Lymphoma; Ovarian cancer
Most Recent Events
- 31 May 2024 Efficacy and adverse events data from phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 28 May 2024 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Combination therapy, Inoperable/Unresectable, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO)
- 28 May 2024 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease) in Canada (PO)